Glycine News and Research

RSS

FDA approves Biotest's BIVIGAM to treat Primary Humoral Immunodeficiency

Biotest Pharmaceuticals Corporation (BPC), a wholly owned U.S. subsidiary of Biotest AG, recently announced the U.S. Food and Drug Administration's (FDA) approval of BIVIGAM, its new intravenous immune globulin, for the treatment of patients with Primary Humoral Immunodeficiency (PI).

31 Jan 2013

Biotest receives FDA approval for BIVIGAM to treat primary humoral immunodeficiency

Biotest AG announced today that Biotest Pharmaceuticals Corporation received approval for BIVIGAM for the treatment of patients with Primary Humoral Immunodeficiency (PI) from the U.S. Food and Drug Administration (FDA).

20 Dec 2012

Dendritic spines respond to and process synaptic inputs both chemically and electrically

It's the least understood organ in the human body: the brain, a massive network of electrically excitable neurons, all communicating with one another via receptors on their tree-like dendrites. Somehow these cells work together to enable great feats of human learning and memory. But how?

6 Dec 2012

Rethinking therapy decisions in autoimmune encephalopathy

Researchers say that diagnosis and management of encephalopathies may need to be rethought, as many patients who test negative for the relevant antibody still benefit from immunotherapy.

4 Dec 2012

Anesthetics can help reduce risk of cardiac surgery drug-associated seizures

Two drugs commonly given during cardiac surgery can lead to convulsive seizures, but anesthetics can help cut the risk, according to new research from the Faculty of Medicine at the University of Toronto.

27 Nov 2012

Antifibrinolytics inhibit glycine receptor activity in the brain and cause seizures

Antifibrinolytic drugs are frequently used to prevent blood loss during surgery, but sometimes cause convulsive seizures. In this issue of the Journal of Clinical Investigation, researchers led by Beverly Orser at the University of Toronto investigated the molecular mechanisms that underlie this side effect.

27 Nov 2012

Autoantibody aids identification of hyperexcitability disorders

Researchers have found that testing for a glycine receptor autoantibody aids the identification of a broad spectrum of autoimmune brainstem/spinal cord hyperexcitability disorders.

29 Oct 2012

MRC awards grant to design new drug for treatment of chronic pain

Scientists at the University of Liverpool and the Royal Liverpool University Hospital have been awarded -1.4 million to design a new drug for the treatment of chronic pain.

24 Aug 2012

Studies identify genetic mutations that play important roles in startle disease

Two studies published in the Journal of Biological Chemistry identify genetic mutations that play important roles in the condition commonly referred to as startle disease. Startle disease is characterized by an exaggerated response to noise and touch, which can interfere with breathing, cause catastrophic falls and even result in death.

8 Aug 2012

Powerful brain chemical systems work together to paralyze skeletal muscles during REM sleep

Two powerful brain chemical systems work together to paralyze skeletal muscles during rapid eye movement (REM) sleep, according to new research in the July 11 issue of The Journal of Neuroscience. The finding may help scientists better understand and treat sleep disorders, including narcolepsy, tooth grinding, and REM sleep behavior disorder.

12 Jul 2012

Clinical utility of Metabolon's Quantose IR test to be showcased at ADA meeting

Metabolon, Inc. announces that the clinical utility of the Company's lead diagnostic product Quantose IR will be featured in five poster presentations at the 72nd Annual Scientific Sessions of the American Diabetes Association (ADA) being held June 8-12 in Philadelphia.

12 Jun 2012

Naurex commences GLYX-13 Phase II trial in treatment-resistant depression

Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today announced that it has initiated a Phase II clinical trial of its lead compound GLYX-13.

22 Jun 2011

Naurex announces completion of $18 million Series A financing

Naurex Inc., a clinical-stage company developing innovative treatments to address unmet needs in psychiatry and neurology, today announced the completion of an $18 million Series A financing led by Adams Street Partners and Latterell Venture Partners.

11 May 2011

Previously unknown mechanism blocks rewarding effects of alcohol on the brain

In order to develop new medications for alcoholism, researchers need to understand how alcohol acts on the brain's reward system. A previously unknown mechanism has been shown to block the rewarding effects of alcohol on the brain, reveals a thesis from the University of Gothenburg, Sweden.

5 Apr 2011

Researchers find kidney-specific gene defects may increase risk of heart failure

Scientists have identified the first DNA sequence variant common in the population that is not only associated with an increased risk of heart failure, but appears to play a role in causing it.

18 Jan 2011

Genentech announces Phase II study results of RG1678 for treatment of schizophrenia

Genentech, Inc., a member of the Roche Group, today announced eight-week results from a Phase II study of RG1678, its investigational first-in-class glycine reuptake inhibitor for the treatment of schizophrenia.

6 Dec 2010

Naurex's antidepressant shares efficacy mechanisms with NMDA receptor antagonist ketamine

Naurex Inc., a company developing innovative treatments to address unmet needs in psychiatry and neurology, today reported that data presented at Neuroscience 2010 show that GLYX-13, its clinical-stage candidate for the treatment of depression, shares key mechanistic features associated with the antidepressant efficacy of the NMDA receptor antagonist ketamine.

18 Nov 2010

Novel bioelectric signals can cause stem cells to trigger melanoma-like growth in pigment cells

Biologists at Tufts University School of Arts and Sciences have discovered that a change in membrane voltage in newly identified "instructor cells" can cause stem cells' descendants to trigger melanoma-like growth in pigment cells. The Tufts team also found that this metastatic transformation is due to changes in serotonin transport. The discovery could aid in the prevention and treatment of diseases like cancer and vitiligo as well as birth defects.

19 Oct 2010

Cigarette smoke inhibits LTA4H enzyme, regulates body's response to inflammation: Study

Cigarette smoke shuts off a key enzyme in airways that regulates the body's response to inflammation, according to findings from the University of Alabama at Birmingham published online today at Science Express.

3 Sep 2010

Naurex announces GLYX-13 molecule recognized in “Top 10 to Watch" list for depression treatment

Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders, today reported that its clinical stage candidate for the treatment of depression, GLYX-13, and its second-generation NRX-1050 series have been selected for inclusion on Windhover's list of the "Top 10 Most Interesting Neuroscience Projects to Watch."

31 Aug 2010